A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2034-07-31

Target enrollment:

Participant gender:

The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.